A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures

一项随机、双盲、安慰剂对照、多中心研究,旨在评估辅助使用塞诺巴酯治疗亚洲局灶性癫痫患者的疗效和安全性。

阅读:1

Abstract

OBJECTIVES: This randomized, double-blind, placebo-controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. METHODS: Adults 18-70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic-clonic) during an 8-week baseline, despite treatment with 1-3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18-week titration phase and a 6-week maintenance phase. The primary efficacy analysis was a hierarchical step-down comparison of the percent change from baseline in 28-day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. RESULTS: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was -25.9% for placebo vs -42.6%, -78.3%, and -100% for cenobamate 100, 200, and 400 mg/day, respectively (all p's < .001). During the 12-week period encompassing the last 6 weeks of titration and the 6-week maintenance phase (secondary outcome), the median percent change in seizure frequency was -20.1% for placebo vs -42.6%, -77.1%, and -89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure-free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12-week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment-emergent adverse events in cenobamate patients (≥20%) were dose-related dizziness and somnolence. SIGNIFICANCE: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose-related fashion and was generally well tolerated.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。